Connect with us

Press Releases

Azura Ophthalmics Appoints Dr. Steven Altschuler as Chair of the Board of Directors

Dr. Altschuler is a biopharma industry veteran with more than 20 years of experience in building, scaling and leading world-class healthcare and biotechnology companies.

mm

Published

on

(PRESS RELEASE) TEL AVIV, Israel & MELBOURNE, AUSTRALIA — Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian Gland Dysfunction (MGD) and related eye diseases, today announced the appointment of Steven M. Altschuler, M.D., as chair of its board of directors. Dr. Altschuler brings over 20 years of experience building, scaling and leading world-class healthcare and biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners. Previously, he co-founded Spark Therapeutics and served as board chair through its progress from private company to IPO and later acquisition by Roche in 2019.

“We are very pleased to welcome Steven as chair of Azura’s board of directors,” said Marc Gleeson, chief executive officer of Azura Ophthalmics. “Steven has a proven track record of scaling both private and public organizations and has distinguished himself as a strategic thinker and leader in biotech. We look forward to Steve’s contributions and the unique perspective he will bring to our business with his deep healthcare experience, including ophthalmology.”

Trained as a pediatric gastroenterologist, Dr. Altschuler formerly held CEO positions at the Children’s Hospital of Philadelphia (CHOP), one of the United States leading children’s hospitals, and the University of Miami Health System. Currently, Dr. Altschuler is the chair of the board of AsclepiX Therapeutics, 89Bio and PlateletBio, serves on the boards of ImVax, Orchard Therapeutics, Affinivax and WW (formerly Weight Watchers International), and is an independent trustee of the Brigham and Women’s Physician Organization. Dr. Altschuler holds a bachelor’s degree in mathematics and an M.D. from Case Western Reserve University.

“I believe Azura is well-positioned to upend the treatment of ocular surface disease and transform the ophthalmic market with its robust therapeutic portfolio,” said Dr. Altschuler. “I look forward to working closely with the management team and current board as we continue to advance our lead product candidate AZR-MD-001 and pipeline to bring innovative ophthalmic therapies to patients.”

SPONSORED VIDEO

Shamir Glacier Plus Metaform: Stronger. Thinner. Lighter.

It’s time for a new compromise-free lens technology that completely changes our concept of what's possible. Glacier Plus™ Metaform enables customers to enjoy strength and safety alongside the aesthetics of thin and light lenses. Now Available: The next technical revolution in the world of optics.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular